129 related articles for article (PubMed ID: 12353513)
1. Oophorectomy in carriers of BRCA mutations.
Whitfield GA
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
[No Abstract] [Full Text] [Related]
2. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
Haber D
N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
[No Abstract] [Full Text] [Related]
4. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
5. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Mahajan NN
Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
[No Abstract] [Full Text] [Related]
6. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
7. Oophorectomy in carriers of BRCA mutations.
Zhuang SH; Leonard GD; Swain SM
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12324566
[No Abstract] [Full Text] [Related]
8. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
9. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
[No Abstract] [Full Text] [Related]
10. Oophorectomy in carriers of BRCA mutations.
Peshkin BN; DeMarco TA; Schwartz MD
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353511
[No Abstract] [Full Text] [Related]
11. Oophorectomy in carriers of BRCA mutations.
Anderson WF; Brawley OW; Chang S
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
[No Abstract] [Full Text] [Related]
12. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
[TBL] [Abstract][Full Text] [Related]
13. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
14. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
[TBL] [Abstract][Full Text] [Related]
15. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
Kauff ND; Barakat RR
Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
[No Abstract] [Full Text] [Related]
16. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
17. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
Chapman JS; Powell CB; McLennan J; Crawford B; Mak J; Stewart N; Chen LM
Gynecol Oncol; 2011 Aug; 122(2):339-43. PubMed ID: 21531449
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
Matloff ET; Barnett RE; Bober SL
Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
[TBL] [Abstract][Full Text] [Related]
20. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]